Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological research in Italy from 2020 to 2023.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2023
Same author

Medical versus neurosurgical treatment in ICH patients: a single center experience.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2023
Same author

Key design elements of successful acute ischemic stroke treatment trials.

Neurological research and practice·2023
Same author

Fatal intracranial haemorrhage occurring after oral anticoagulant treatment initiation for secondary stroke prevention in patients with atrial fibrillation.

European journal of neurology·2020
Same author

Optimization of stroke prevention: colchicine may be an option.

European journal of neurology·2020
Same author

Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity.

European journal of neurology·2020

Related Experiment Video

Updated: Jun 19, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:45

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

Hormone-replacement therapy, dementia and stroke.

Amr Billeci1, V Caso, M Paciaroni

  • 1University of Perugia, Stroke Unit and Division of Cardiovascular Medicine, Ospedale SM della Misericordia, Sant'Andrea delle Fratte, 06129 Perugia, Italy. antobilly@yahoo.it.

Women'S Health (London, England)
|October 7, 2009
PubMed
Summary
This summary is machine-generated.

Hormone-replacement therapy (HRT) does not protect against Alzheimer's disease or stroke in postmenopausal women. Evidence indicates HRT may increase vascular risk, negating potential benefits for cognitive decline and cerebrovascular health.

Related Experiment Videos

Last Updated: Jun 19, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:45

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

Area of Science:

  • Neuroscience
  • Endocrinology
  • Cardiovascular Science

Background:

  • Hormone-replacement therapy (HRT) has been utilized for over four decades to alleviate perimenopausal symptoms.
  • Estrogens were hypothesized to offer neuroprotection against Alzheimer's disease and reduce stroke risk due to their association with higher premenopausal hormone levels.

Purpose of the Study:

  • To evaluate the efficacy of HRT in preventing dementia and stroke in postmenopausal women.
  • To examine the impact of HRT on vascular risk based on current clinical evidence.

Main Methods:

  • Review and analysis of data from major clinical trials and observational studies on HRT.
  • Examination of evidence regarding HRT's effects on cognitive function, dementia risk, and stroke incidence.

Main Results:

  • Large clinical trials found no cognitive benefits or reduction in dementia risk with HRT.
  • Observational studies showed inconsistent results for stroke risk, with recent evidence suggesting an increased vascular risk.
  • HRT demonstrated no beneficial effect on dementia or stroke risk reduction.

Conclusions:

  • HRT does not provide a protective effect against dementia or stroke in postmenopausal women.
  • Current evidence suggests HRT may elevate vascular risk, challenging previous assumptions about its cardioprotective and cerebroprotective qualities.